Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin degludec/liraglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified April 2016

The Efficacy and Safety of Chinese Herbal Medicine YH1 as Add-On Medication in Poorly Controlled Type 2 Diabetes Patients: A Randomized Double-Blind Placebo-Controlled Trial

Condition:   Poorly Controlled Type 2 Diabetes Patients
Intervention:   Drug: Chinese herbal medicine,YH1
Sponsor:   Chang Gung Memorial Hospital
Not yet recruiting - verified March 2016

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Not yet recruiting - verified April 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Not yet recruiting - verified April 2016

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Empagliflozin and Linagliptin;   Drug: Metformin and Insulin sc
Sponsors:   Institut für Pharmakologie und Präventive Medizin;   University of Erlangen-Nürnberg Medical School
Recruiting - verified April 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified April 2016

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

Condition:   Type 2 Diabetes
Intervention:   Drug: Evogliptin, Pioglitazone, Evogliptin+Pioglitazone
Sponsor:   Dong-A ST Co., Ltd.
Not yet recruiting - verified April 2016

Type 2 Diabetes Affect Exercise Induced Improvement in Insulin Sensitivity

Condition:   Insulin Sensitivity/Resistance
Intervention:   Other: 8 weeks of combined exercise intervention
Sponsor:   University of Texas, El Paso
Recruiting - verified April 2016

CSII Pilot in Adolescents With Type 2 Diabetes

Condition:   Diabetes
Intervention:   Device: MMT 723
Sponsor:   New York University School of Medicine
Recruiting - verified April 2016

ForgIng New Paths to Prevent DIabeTes (FINDIT)

Condition:   Prediabetes
Interventions:   Behavioral: Blood Test Group Intervention;   Behavioral: Brochure Group Intervention
Sponsor:   VA Office of Research and Development
Recruiting - verified April 2016

Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Aspirin
Sponsor:   Peking Union Medical College Hospital
Not yet recruiting - verified April 2016

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Device: Auto-injector
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified April 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Not yet recruiting - verified April 2016

A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:   Other: Use of digital disease management tool in participants with T2DM
Sponsors:   AstraZeneca;   Parexel
Not yet recruiting - verified April 2016

Ultrasound Detection of Subclinical Lipohypertrophy in Diabetes

Conditions:   Diabetes Mellitus;   Lipohypertrophy
Interventions:   Other: Lipohypertrophy;   Other: Normal Subcutaneous Tissue
Sponsor:   University of British Columbia
Not yet recruiting - verified April 2016

Evaluation of a Diabetes Self-Management Education Program for Non-Intensified Insulin Therapy in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: MEDIAS 2 CT;   Behavioral: Current CT program
Sponsor:   Forschungsinstitut der Diabetes Akademie Mergentheim
Active, not recruiting - verified April 2016

Clinical Observation of Coronary Arterial Microcirculation Dysfunction in Diabetic Patients With Non- Obstructive Coronary Artery Disease

Conditions:   Complications of Diabetes Mellitus;   Coronary Artery Disease
Intervention:  
Sponsor:   Shaanxi Provincial People's Hospital
Recruiting - verified April 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified April 2016

Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10mg;   Drug: Placebo 10mg
Sponsor:   Yonsei University
Not yet recruiting - verified April 2016

Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics

Conditions:   Healthy;   Type 2 Diabetes Mellitus
Interventions:   Drug: GMC-252-L-Lysine Salt;   Other: Placebo
Sponsors:   Genmedica Therapeutics S.L.;   Simbec Research
Not yet recruiting - verified April 2016

Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion

Condition:   Type 2 Diabetes
Interventions:   Other: Mixed meal test;   Drug: Vildagliptin;   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin;   Other: Diet and exercise
Sponsor:   Michael A. Nauck
Completed - verified April 2016

Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes

Conditions:   Erectile Dysfunction;   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus
Interventions:   Biological: HUC-MSCs;   Biological: Injectable Collagen Scaffold + HUC-MSCs
Sponsors:   Chinese Academy of Sciences;   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recruiting - verified April 2016

Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

Condition:   Diabetes Mellitus
Interventions:   Drug: Lixisenatide;   Other: Placebo
Sponsors:   Seoul National University Hospital;   Seoul National University
Recruiting - verified February 2016

Coronary Artery Disease Progression in Patients With Prediabetes

Conditions:   Coronary Artery Disease;   Atherosclerosis;   Prediabetic State
Interventions:   Drug: Metformin;   Behavioral: Lifestyle recommendations
Sponsor:   Pauls Stradins Clinical University Hospital
Recruiting - verified April 2016

Effect of Non Surgical Treatment of Periodontitis on Diabetes Control

Conditions:   Periodontitis;   Diabetes
Intervention:   Procedure: non-surgical periodontal treatment
Sponsor:   Yaounde Central Hospital
Completed - verified April 2016

Emotional Disorders and Outcomes in Adults With Type 2 Diabetes Mellitus at Primary Care

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Universiti Putra Malaysia;   Ministry of Health, Malaysia;   UMC Utrecht
Enrolling by invitation - verified April 2016

Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: VEMOFIT;   Behavioral: Attention-meetings (AG)
Sponsors:   Universiti Putra Malaysia;   Ministry of Health, Malaysia;   UMC Utrecht
Enrolling by invitation - verified April 2016

Training in the Fasted State, Glucose Metabolism and Energy Balance

Condition:   Glucose Metabolism Disorders
Interventions:   Behavioral: Exercise;   Behavioral: Breakfast;   Behavioral: Maintain habitual habits
Sponsor:   University of Bath
Not yet recruiting - verified April 2016

The Role of Values, Acceptance, and Mindfulness Strategies in Long Term Weight Management

Condition:   Obesity
Intervention:   Behavioral: Acceptance and Commitment Therapy
Sponsor:   Nova Scotia Health Authority
Not yet recruiting - verified April 2016

G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)

Conditions:   Type 2 Diabetes;   Impaired Glucose Intolerance
Intervention:  
Sponsor:   Yonsei University
Not yet recruiting - verified April 2016

RISCAID Study: Remote ISchemic Conditioning for Angiopathy In Diabetes

Condition:   Peripheral Arterial Disease
Interventions:   Device: AutoRIC: Remote Ischemic Conditioning;   Device: AutoRIC: Sham device treatment
Sponsors:   Steno Diabetes Center;   Aarhus University Hospital;   German Diabetes Center
Not yet recruiting - verified April 2016

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified April 2016

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Recruiting - verified April 2016

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified April 2016

Balance After Baby Intervention for Women With Recent Gestational Diabetes

Condition:   Gestational Diabetes Mellitus
Intervention:   Behavioral: BABI-2 Lifestyle Intervention
Sponsors:   Brigham and Women's Hospital;   University of Colorado, Denver
Not yet recruiting - verified April 2016

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Condition:   Non Alcoholic Fatty Liver Disease
Intervention:   Drug: Empagliflozin
Sponsor:   Medanta, The Medicity, India
Not yet recruiting - verified April 2016

Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes

Condition:   Healthy
Interventions:   Drug: GMC-252-L-Lysine;   Other: Placebo
Sponsors:   Genmedica Therapeutics S.L.;   Simbec Research
Terminated - verified April 2016

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lyophilized albiglutide DCC pen injector;   Drug: Lyophilized albiglutide DCC pen injector matching placebo;   Drug: Albiglutide liquid auto-injector;   Drug: Albiglutide liquid auto-injector matching placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2016

Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy

Condition:   Type 2 Diabetes
Interventions:   Other: 1: incretin-based therapy;   Other: 2: other antidiabetic
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Assistance Publique Hopitaux De Marseille;   Institut National de la Santé Et de la Recherche Médicale, France;   Centre National de la Recherche Scientifique, France;   Collège de France;   University of Paris 5 - Rene Descartes;   Pierre and Marie Curie University;   University Paris 7 - Denis Diderot;   Aix Marseille Université
Recruiting - verified April 2016

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

Conditions:   Age-Related Macular Degeneration;   Macular Degeneration, Age-Related;   Dry Macular Degeneration;   Geographic Atrophy
Intervention:   Drug: Metformin
Sponsor:   University of California, San Francisco
Recruiting - verified April 2016

Dapagliflozin Effect on Symptoms and Biomarkers in Diabetes Patients With Heart Failure

Condition:   Chronic Heart Failure With Reduced Systolic Function
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin matching placebo
Sponsor:   Saint Luke's Health System
Recruiting - verified April 2016

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Condition:   Dyslipidemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: statins;   Drug: ezetimibe;   Drug: fenofibrate;   Drug: nicotinic acid;   Drug: omega-3 fatty acids
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2016

Efficacy and Mechanism Study of Bariatric Surgery to Treat Moderate to Severe Obesity in Han Chinese Population

Condition:   Morbid Obesity
Intervention:   Procedure: Sleeve gastrectomy
Sponsor:   Shanghai Jiao Tong University School of Medicine
Recruiting - verified January 2016

Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2016

Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo

Condition:   Hyperglycaemia
Interventions:   Other: Control without pomegranate juice;   Other: Test with pomegranate juice
Sponsor:   University of Leeds
Completed - verified April 2016

Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1

Conditions:   Overweight;   Diabetes Mellitus, Type 2
Interventions:   Procedure: Sleeve Gastrectomy with Ileal Transposition;   Procedure: Sleeve Gastrectomy with Transit Bipartition;   Other: Medical Treatment
Sponsor:   Turkish Metabolic Surgery Foundation
Enrolling by invitation - verified April 2016

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2016

Optimization of Interval-training in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: CON;   Behavioral: IW-60;   Behavioral: IW-45
Sponsor:   Rigshospitalet, Denmark
Recruiting - verified April 2016

Interval-training and Appetite Regulation in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: CON;   Behavioral: CW;   Behavioral: IW
Sponsor:   Rigshospitalet, Denmark
Recruiting - verified April 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2016

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Ipragliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified April 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified April 2016

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabestes and CKD3

Condition:   Type 2 Diabetes Mellitus, CKD3 and Albuminuria
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg;   Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Sponsor:   AstraZeneca
Recruiting - verified April 2016

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Diabetes Mellitus, Type 2
Interventions:   Drug: Biphasic Remogliflozin Etabonate;   Other: Placebo
Sponsors:   BHV Pharma;   Integrium
Active, not recruiting - verified March 2016

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Biological: MEDI-4166;   Biological: Placebo
Sponsor:   MedImmune LLC
Recruiting - verified April 2016

Human Intestinal Peptides Evaluation and Research

Conditions:   Obesity;   Diabetes Mellitus, Type 2
Intervention:   Other: blood sample analysis
Sponsor:   Turkish Metabolic Surgery Foundation
Enrolling by invitation - verified April 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified March 2016

Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Procedure: LSG;   Drug: CMT
Sponsors:   Azienda Ospedaliera Santa Maria, Terni, Italy;   Ethicon Endo-Surgery
Recruiting - verified April 2016

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

Conditions:   Polycystic Ovary Syndrome;   Non-Alcoholic Fatty Liver Disease;   Metabolic Syndrome
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsor:   Columbia University
Recruiting - verified April 2016

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Condition:   Elevated Body Mass Index
Interventions:   Drug: LIK066;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed - verified April 2016

Effect of Dapagliflozin on Glycemic Variability

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The Catholic University of Korea;   AstraZeneca;   Severance Hospital;   Eulji General Hospital;   Kyung Hee University Hospital at Gangdong
Recruiting - verified April 2016

The Diabetes Medication Adherence Promotion Intervention Trial

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Diabetes MAP Intervention
Sponsors:   Vanderbilt University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2016

Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo.

Condition:   Hyperglycaemia
Interventions:   Other: Control (109 g white bread);   Dietary Supplement: Dose 1;   Dietary Supplement: Dose 2
Sponsor:   University of Leeds
Completed - verified April 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2016

Incretin-based Drugs and the Risk of Heart Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DPP-4 inhibitors;   Drug: GLP-1 analogs;   Drug: Insulins;   Drug: Biguanides;   Drug: Sulfonylureas;   Drug: Thiazolidinediones;   Drug: Alpha-glucosidase inhibitors;   Drug: Meglitinides
Sponsors:   Canadian Network for Observational Drug Effect Studies, CNODES;   Drug Safety and Effectiveness Network, Canada;   Canadian Institutes of Health Research (CIHR)
Completed - verified April 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified April 2016

Prohealth@Home: A Feasibility Study Investigating the Use of a Lifestyle App in People at Risk of Type 2 Diabetes

Condition:   Pre-diabetes
Intervention:   Behavioral: Lifestyle counselling
Sponsor:   University of Plymouth
Completed - verified April 2016

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Dapagliflozin
Sponsors:   Seoul National University Hospital;   AstraZeneca
Completed - verified April 2016

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin glargine;   Drug: Insulin aspart;   Drug: Supplemental insulin aspart
Sponsor:   Emory University
Recruiting - verified April 2016

Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea

Conditions:   Diabetes;   Obstructive Sleep Apnea
Interventions:   Device: CPAP;   Other: Control
Sponsors:   Nordsjaellands Hospital;   Aarhus University Hospital
Recruiting - verified February 2016

Weight Changes During and After Pregnancy in Women With Gestational Diabetes

Condition:   Gestational Diabetes Mellitus
Intervention:  
Sponsors:   Vanderbilt University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified April 2016

Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Endoplasmic Reticulum Stress
Intervention:   Other: No intervention
Sponsor:   Assistance Publique - Hôpitaux de Paris
Active, not recruiting - verified April 2016

Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes

Condition:   Diabetes Mellitus
Interventions:   Other: Shared decision-making aid;   Other: Generic hard copy diabetes resources;   Other: Generic online diabetes resources
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified April 2016

Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2016

The MoMMii Study. Diabetes Prevention Intervention on Families With Past Gestational Diabetes

Condition:   Gestational Diabetes Mellitus With Baby Delivered
Intervention:   Behavioral: Nutrition/physical activity intervention
Sponsors:   McGill University Health Center;   The Lawson Foundation
Active, not recruiting - verified April 2016

Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes

Conditions:   Charcot Arthropathy;   Type 2 Diabetes
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Hamad Medical Corporation;   Weill Cornell Medical College in Qatar
Recruiting - verified April 2016

Interval-training in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Control;   Behavioral: Continuous walking;   Behavioral: Interval walking
Sponsor:   Rigshospitalet, Denmark
Completed - verified April 2016

Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer

Condition:   Epithelial Ovarian Cancer
Interventions:   Drug: Metformin;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   University Medical Center Groningen
Recruiting - verified April 2016

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Conditions:   Vascular Diseases;   Hypercholesterolemia;   Diabetes Mellitus
Interventions:   Dietary Supplement: Plant sterols;   Dietary Supplement: Placebo product
Sponsors:   Unilever R&D;   CSIRO
Recruiting - verified April 2016

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2016

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Active, not recruiting - verified April 2016

The Practical Evidence of Antidiabetic Combination Therapy in Korea

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: alogliptin;   Drug: Pioglitazone;   Drug: alogliptin + pioglitazone
Sponsors:   Kun-Ho Yoon;   Takeda
Recruiting - verified April 2016

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2016

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2016

Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Gemigliptin;   Drug: Placebo
Sponsors:   Seoul National University Hospital;   LG Life Sciences
Completed - verified July 2014

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2016

Improving Medication Adherence in Older African Americans With Diabetes

Conditions:   Type 2 Diabetes;   Mild Cognitive Impairment
Interventions:   Behavioral: Primary Care-Occupational Therapy;   Behavioral: Enhanced Usual Care
Sponsors:   Thomas Jefferson University;   Johns Hopkins University
Recruiting - verified April 2016

Effect of Intranasal Insulin on LH Concentrations in Man

Condition:   Hypogonadotropic Hypogonadism
Interventions:   Drug: intranasal insulin;   Drug: placebo (intranasal saline)
Sponsor:   Texas Tech University Health Sciences Center
Recruiting - verified April 2016

Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)

Conditions:   Obesity;   Type 2 Diabetes
Intervention:  
Sponsors:   Translational Research Institute for Metabolism and Diabetes, Florida;   Sanford-Burnham Medical Research Institute
Active, not recruiting - verified April 2016

Glycemic Durability After Metformin Failure

Condition:   Type 2 Diabetes
Interventions:   Drug: Glimepiride;   Drug: Vildagliptin;   Drug: Pioglitazone;   Drug: Canagliflozin
Sponsor:   Second University of Naples
Recruiting - verified November 2015

Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: DbXell;   Dietary Supplement: Placebo
Sponsors:   Laniado Hospital;   K.G.S Research & Entrepreneurship, Israel
Recruiting - verified April 2016

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Linagliptin 5 mg QD (N=24);   Drug: Glimepiride 1 mg QD (N=24)
Sponsor:   VU University Medical Center
Active, not recruiting - verified April 2016

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified April 2016

Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

Conditions:   Type 2 Diabetes;   Obesity;   Diabesity
Interventions:   Drug: Liraglutide;   Device: Duodenal-jejunal bypass liner - Endobarrier device
Sponsors:   Sandwell & West Birmingham Hospitals NHS Trust;   Association of British Clinical Diabetologists
Active, not recruiting - verified April 2016

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

Condition:   Type 2 Diabetes
Intervention:   Drug: Bromocriptine mesylate
Sponsor:   VeroScience
Recruiting - verified April 2016

Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria

Condition:   Diabetic Nephropathy
Interventions:   Drug: colchicine 0.5mg/d;   Drug: placebo 0.5mg/d
Sponsor:   Chongqing Medical University
Active, not recruiting - verified April 2016

Individually Tailored Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Hypertension
Intervention:   Other: Individual treatment
Sponsors:   Odense University Hospital;   Region of Southern Denmark;   Hospital of South West Denmark;   General Practice Research Database
Enrolling by invitation - verified April 2016

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2016

Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

Condition:   T2DM
Interventions:   Drug: Gemigliptin;   Drug: Gemigliptin placebo
Sponsor:   LG Life Sciences
Completed - verified April 2016

Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Condition:   Type II Diabetes Mellitus
Intervention:   Drug: Pioglitazone
Sponsor:   Takeda
Active, not recruiting - verified April 2016

Improving Self Management Skills of Older Adults With Diabetes

Conditions:   Type 2 Diabetes;   Diabetes
Intervention:   Behavioral: Diabetes Self Management Program
Sponsors:   Stanford University;   HealthCore, Inc.
Active, not recruiting - verified April 2016

BIOFLOW III Asia Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Asia Pacific Pte Ltd
Active, not recruiting - verified April 2016

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified April 2016

Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care

Condition:   Type 2 Diabetes
Interventions:   Other: Remote, personalized type 2 diabetes care.;   Other: Usual Endocrine care.
Sponsor:   University of Michigan
Active, not recruiting - verified April 2016

GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
Sponsor:   Bayer
Withdrawn - verified March 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2016

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified April 2016

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin detemir;   Drug: insulin detemir
Sponsor:   Novo Nordisk A/S
Completed - verified April 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

Conditions:   Diabetes;   Atherosclerosis
Interventions:   Drug: sitagliptin;   Drug: Placebo
Sponsors:   Medical College of Wisconsin;   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2016

Lifestyle Intervention for Treatment of Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Behavioral: Community Lifestyle Weight Loss (LWL);   Behavioral: Diabetes Self Management (DSM)
Sponsors:   Wake Forest University;   National Institute on Minority Health and Health Disparities (NIMHD)
Active, not recruiting - verified April 2016

Activator and Type II Diabetics

Condition:   Type II Diabetes
Intervention:   Other: Chiropractic Adjustment
Sponsor:   Life University
Completed - verified September 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

Almased Multi-Center Diabetes Intervention Trial

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Dietary Supplement: Almased Meal Replacement Powder;   Behavioral: Group-Based Lifestyle Intervention
Sponsors:   Wake Forest School of Medicine;   University of Freiburg;   University of Campinas, Brazil;   London Metropolitan University;   University of Mysore, India
Completed - verified April 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2016

May Metformin be Used in Renal Failure?

Condition:   Renal Disorder Associated With Type II Diabetes Mellitus
Intervention:   Drug: Metformin
Sponsors:   Centre Hospitalier Universitaire, Amiens;   Merck Serono International SA
Completed - verified April 2016

The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: Anti-oxidant and micronutrient;   Drug: Placebo
Sponsor:   Walter Reed National Military Medical Center
Completed - verified April 2016

An Educational Intervention for Type 2 Diabetes Patients

Condition:   Diabetes Mellitus
Interventions:   Behavioral: Intervention Video;   Behavioral: Control
Sponsor:   VA Office of Research and Development
Recruiting - verified April 2016

High Protein Breakfast on Appetite, Postprandial Glycemia and Weight Loss in T2D

Conditions:   Obese;   Pre-diabetes
Interventions:   Other: Arm 1 Whey Breakfast;   Other: Arm 2 No Whey Breakfast;   Other: Arm 3 Low Protein Breakfast
Sponsors:   Hospital de Clinicas Caracas;   Tel Aviv University
Active, not recruiting - verified September 2015

Biomarkers of Diabetic Retinopathy Progression

Conditions:   Type 2 Diabetes Mellitus;   Mild Nonproliferative Diabetic Retinopathy
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting - verified April 2016

Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

Conditions:   Type 2 Diabetes Mellitus;   Ischemic Heart Disease
Interventions:   Drug: Metformin plus vildagliptin;   Drug: Metformin only
Sponsor:   Sheba Medical Center
Completed - verified April 2016

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2016

Environmental Triggers Of Cardiometabolic Disease

Condition:   Metabolic Syndrome X
Intervention:  
Sponsors:   Sanjay Rajagopalan;   University of Michigan;   Peking Union Medical College;   National Institute of Environmental Health Sciences (NIEHS)
Completed - verified April 2016

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2016

Glutathione in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Proteinuria;   Oxidative Stress
Interventions:   Drug: N-acetylcysteine placebo + silibin placebo;   Drug: N-acetylcysteine active + silibin placebo;   Drug: N-acetylcysteine placebo + silibin active;   Drug: N-acetylcysteine active + silibin active;   Drug: N-acetylcysteine active + high-dose silibin active
Sponsors:   VA Office of Research and Development;   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting - verified April 2016

Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes

Conditions:   Overweight;   Obesity;   Type 2 Diabetes
Interventions:   Behavioral: Caloric restriction;   Behavioral: Diet intervention and structured exercise training program
Sponsor:   Institut de Recherches Cliniques de Montreal
Completed - verified April 2016

Effects of Hi-maize Resistant Starch on Insulin Sensitivity

Condition:   Insulin Resistance
Interventions:   Other: Hi-maize starch (Low dose);   Other: Hi-maize starch (High-dose);   Other: Control (starch)
Sponsor:   National Starch LLC
Completed - verified September 2010

Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Saline
Sponsor:   University of Nottingham
Completed - verified April 2016

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Abnormal Glucose Metabolism;   Type 2 Diabetes
Intervention:   Behavioral: Assignment of a Lay Patient Partner
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 2016

Prevention of Cystic Fibrosis Diabetes

Conditions:   Cystic Fibrosis;   Prediabetes
Intervention:   Drug: Sitagliptin
Sponsor:   Emory University
Recruiting - verified April 2016

Spanish Diabetes Self-Management Program

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Spanish Diabetes Self-Management Program
Sponsor:   Stanford University
Completed - verified April 2016